Breast Cancer Treatments: Subtypes, Biomarkers, and What Comes Next

Breast cancer treatment can feel complex because “breast cancer” is actually several different diseases. This guide explains the subtypes that drive decisions, the tools used today, and the sequencing mindset (“what we do next if this stops working”).

Important: This is educational information, not medical advice. Your plan depends on stage, tumor subtype, biomarker results, overall health, and preferences.

---

60-second orientation

• Breast cancer is usually treated as three major diseases:
  1. Hormone receptor–positive / HER2-negative (HR+ / HER2-)
  2. HER2-positive (HER2+)
  3. Triple-negative breast cancer (TNBC)
• Stage matters, but biology often determines the drug plan.
• Newer therapies like antibody–drug conjugates (ADCs) are changing treatment options in several settings.

---

Key terms (defined once)

• HR+ (hormone receptor–positive): the tumor has estrogen and/or progesterone receptors.
• HER2 (human epidermal growth factor receptor 2): a growth signaling protein; tumors can be HER2-positive.
• TNBC (triple-negative breast cancer): estrogen receptor–negative, progesterone receptor–negative, HER2-negative.
• Systemic therapy: medicines that treat the whole body (chemotherapy, hormone therapy, targeted therapy, immunotherapy).
• ADC (antibody–drug conjugate): an antibody that targets a marker on cancer cells and delivers a linked chemotherapy payload.

---

Step 1: subtype (this changes everything)

1) HR+ / HER2-

Often driven by estrogen signaling. Treatment frequently involves endocrine (hormone-blocking) therapy, often combined with targeted partners depending on stage and setting.

2) HER2+

HER2 is a target with several effective HER2-directed therapies. Many plans revolve around HER2-targeted medicines plus other tools as needed.

3) TNBC

Historically more chemo-driven. Today, treatment can include immunotherapy in selected settings, and newer drug classes are increasingly important in later lines.

---

Step 2: stage (simplified)

• Early stage (localized): treatment may aim for cure using surgery ± radiation plus systemic therapy based on risk and subtype.
• Locally advanced: typically uses combinations (systemic therapy plus surgery and/or radiation).
• Metastatic: focuses on long-term control, symptom relief, and sequencing treatments over time.

---

What treatment typically looks like today (by subtype)

A) HR+ / HER2- (the “sequencing” subtype)

Common themes:

• endocrine therapy is foundational
• targeted partners may be added depending on prior treatments and biomarkers
• chemotherapy is used when needed, often later or when disease is aggressive
• ADCs are increasingly part of the later-line toolkit for selected patients

What to ask:

• “Is my cancer endocrine-sensitive right now?”
• “What biomarkers were tested that change treatment options?”
• “What’s our plan if endocrine therapy stops working?”

---

B) HER2+ (HER2-targeted backbone)

Common themes:

• HER2-directed therapies are central across multiple lines
• treatment is usually a combination strategy (HER2-targeted + chemo/other)
• ADCs play a major role in some settings

What to ask:

• “Am I HER2-positive, and how was it tested?”
• “What HER2-directed options exist now, and what comes next if needed?”

---

C) TNBC (risk-driven and often faster-moving)

Common themes:

• chemotherapy remains important
• immunotherapy can be relevant in selected settings
• ADCs may become important after relapse depending on prior therapy and tumor features

What to ask:

• “Is immunotherapy part of my treatment plan, and why?”
• “What’s the plan for monitoring response and managing side effects?”

---

What’s changing now (the themes)

• ADCs are expanding: more cancers and more lines of therapy.
• Biomarker refinement: some markers are increasingly treated as a spectrum rather than a simple yes/no.
• Earlier use of effective drugs: moving therapies into higher-risk early-stage settings to prevent recurrence.
• Better sequencing logic: planning “what’s next” from the start.

---

Questions to ask your care team (high value)

1. What subtype do I have: HR+/HER2-, HER2+, or TNBC?
2. What stage is it, and what is the goal right now (cure vs control)?
3. What biomarkers were tested (and do they change the plan)?
4. What’s the recommended first step, and what alternatives exist?
5. How will we measure whether it’s working?
6. What are the likely side effects and how do we prevent/manage them?
7. If this stops working, what is the next line of therapy?

---